Sarah Skuli

784 total citations
15 papers, 314 citations indexed

About

Sarah Skuli is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Sarah Skuli has authored 15 papers receiving a total of 314 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Hematology and 5 papers in Oncology. Recurrent topics in Sarah Skuli's work include Acute Myeloid Leukemia Research (5 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Cancer-related cognitive impairment studies (2 papers). Sarah Skuli is often cited by papers focused on Acute Myeloid Leukemia Research (5 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Cancer-related cognitive impairment studies (2 papers). Sarah Skuli collaborates with scholars based in United States, France and United Kingdom. Sarah Skuli's co-authors include Betty Tyler, Julie Sesen, Sarah Scotland, Anthony Lemarié, Christine Toulas, Henry Brem, Perrine Dahan, Estelle Saland, Jean-Emmanuel Sarry and Safwan Alomari and has published in prestigious journals such as Journal of Clinical Investigation, Blood and PLoS ONE.

In The Last Decade

Sarah Skuli

12 papers receiving 314 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sarah Skuli United States 7 221 94 69 66 39 15 314
Julia Claasen Germany 8 189 0.9× 98 1.0× 41 0.6× 57 0.9× 23 0.6× 13 280
Christina Barckhausen Germany 7 223 1.0× 66 0.7× 86 1.2× 94 1.4× 15 0.4× 9 320
Reham Helwa Egypt 9 210 1.0× 99 1.1× 75 1.1× 23 0.3× 20 0.5× 19 322
Kayla McEnery United States 8 233 1.1× 133 1.4× 75 1.1× 22 0.3× 32 0.8× 9 401
Scarlett Czarnecki United States 6 198 0.9× 98 1.0× 62 0.9× 28 0.4× 26 0.7× 10 319
Anja Bukovac Croatia 9 179 0.8× 89 0.9× 92 1.3× 36 0.5× 25 0.6× 15 320
Radhika Peddinti United States 8 130 0.6× 69 0.7× 51 0.7× 44 0.7× 9 0.2× 21 270
Mengxi Xiu China 9 175 0.8× 112 1.2× 58 0.8× 18 0.3× 21 0.5× 14 277
Yasuyuki Kaneta Japan 8 174 0.8× 39 0.4× 75 1.1× 44 0.7× 12 0.3× 10 290
M. Nieves Calvo-Vidal United States 7 143 0.6× 70 0.7× 148 2.1× 61 0.9× 10 0.3× 7 290

Countries citing papers authored by Sarah Skuli

Since Specialization
Citations

This map shows the geographic impact of Sarah Skuli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Skuli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Skuli more than expected).

Fields of papers citing papers by Sarah Skuli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Skuli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Skuli. The network helps show where Sarah Skuli may publish in the future.

Co-authorship network of co-authors of Sarah Skuli

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Skuli. A scholar is included among the top collaborators of Sarah Skuli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Skuli. Sarah Skuli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Lee, Yejin, Anne Lorant, Michaël Schnekenburger, et al.. (2025). TP53-agnostic lethality through combined pan-HDAC and CDK inhibition in acute myeloid leukemia. Cancer Letters. 633. 218011–218011.
2.
Alikarami‬, Fatemeh, Simone S. Riedel, Sarah K. Tasian, et al.. (2025). Upfront menin-inhibitor resistance in multiply pretreated leukemias. Experimental Hematology. 153. 105268–105268. 1 indexed citations
3.
4.
Stanley, Robert, Kevin A. Janssen, Mathieu Quesnel-Vallières, et al.. (2024). A mitochondrial surveillance mechanism activated by SRSF2 mutations in hematologic malignancies. Journal of Clinical Investigation. 134(12). 8 indexed citations
5.
Vadakekolathu, Jayakumar, Sarah Skuli, David J. Boocock, et al.. (2024). Multi-Omic Analyses of TP53-Mutated Acute Myeloid Leukemia Identify Prognostic Metabolic Signatures. Blood. 144(Supplement 1). 2911–2911. 2 indexed citations
6.
7.
Khan, Saira, et al.. (2023). NAMPT Haploinsufficiency Is a Therapeutic Vulnerability in High-Risk Myeloid Malignancies. Blood. 142(Supplement 1). 5753–5753.
8.
Skuli, Sarah, Gerald Wertheim, Jimmy P. Xu, et al.. (2023). The Mevalonate Pathway Is a Therapeutic Target in TP53 Mutant Acute Myeloid Leukemia. Blood. 142(Supplement 1). 408–408. 2 indexed citations
9.
Skuli, Sarah, et al.. (2022). Metformin and Cancer, an Ambiguanidous Relationship. Pharmaceuticals. 15(5). 626–626. 35 indexed citations
10.
Freyer, Craig W., Erin M. Bange, Sarah Skuli, et al.. (2021). Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 Deletion Treated With Eculizumab. Clinical Lymphoma Myeloma & Leukemia. 21(11). e845–e849. 9 indexed citations
11.
Skuli, Sarah, Elissa Thorner, Carol Riley, et al.. (2021). Late effects in a high-risk population of breast cancer survivors. Supportive Care in Cancer. 30(2). 1749–1757. 2 indexed citations
12.
Skuli, Sarah, Elissa Bantug, Carol Riley, et al.. (2018). Survivorship care visits in a high-risk population of breast cancer survivors. Breast Cancer Research and Treatment. 173(3). 701–708. 7 indexed citations
13.
Volpin, Francesco, Julie Sesen, Antonella Mangraviti, et al.. (2016). Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic. Oncogene. 36(21). 3037–3047. 46 indexed citations
14.
Sesen, Julie, Perrine Dahan, Sarah Scotland, et al.. (2015). Metformin Inhibits Growth of Human Glioblastoma Cells and Enhances Therapeutic Response. PLoS ONE. 10(4). e0123721–e0123721. 170 indexed citations
15.
Sesen, Julie, Anne Cammas, Sarah Scotland, et al.. (2014). Int6/eIF3e Is Essential for Proliferation and Survival of Human Glioblastoma Cells. International Journal of Molecular Sciences. 15(2). 2172–2190. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julia Claasen Breakdown of academic impact, for papers by Christina Barckhausen Breakdown of academic impact, for papers by Reham Helwa Breakdown of academic impact, for papers by Kayla McEnery Breakdown of academic impact, for papers by Scarlett Czarnecki Breakdown of academic impact, for papers by Anja Bukovac Breakdown of academic impact, for papers by Radhika Peddinti Breakdown of academic impact, for papers by Mengxi Xiu Breakdown of academic impact, for papers by Yasuyuki Kaneta Breakdown of academic impact, for papers by M. Nieves Calvo-Vidal
Rankless by CCL
2026